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Background: Wra is a low-incidence antigen, which is antithetical to the high prevalence
red blood cell antigen, Wrb. Anti-Wra is a naturally occurring antibody that is found in
approximately 1–2% of blood donors. The aim of this study was to determine the frequency
of  Wra and anti-Wra in Brazilian blood donors.
Methods: A total of 1662 Brazilian blood donors were molecularly analyzed using the SNaP-
shot methodology to determine the WR*A/B alleles and to predict the frequency of the Wra
antigen. To detect the anti-Wra, samples from 1049 blood donors were analyzed using a
gel  test with Wr(a+) red blood cells. The serum was treated with dithiothreitol (DTT) to
determine the immunoglobulin classes. Immunoglobulin (Ig)-G isotype classiﬁcation was
performed in a gel test using the IgG1/IgG3 card. A monocyte monolayer assay was employed
to  predict the clinical signiﬁcance of IgG anti-Wra.
Results: Of the 1662 donors, only one sample had the DI*02.03 allele in heterozygous predict-
ing  the Wr(a+b+) phenotype. Anti-Wra was detected in 34 (3.24%) samples, 64.7% in females
and  35.3% in males. Regarding the immunoglobulin class, eight (23.5%) cases of anti-Wra
were classiﬁed as IgG and 26 (76.5%) as IgM. Of the eight cases of IgG anti-Wra, four were
IgG1,  two were IgG3 and three anti-Wra were not IgG3 or IgG1, and thus probably IgG2 or
IgG4. The results of the monocyte monolayer assay showed that IgG anti-Wra might be of
clinical signiﬁcance.
Conclusion: This study shows a very low frequency (0.06%) of the Wra antigen in Brazilian
blood  donors. Additionally, it shows that the frequency of anti-Wra in this population is
higher than previously reported.© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
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he Diego blood group system is carried on band 3, a multi-
ass membrane glycoprotein, which is encoded by the SLC4A1
ene. The Diego system is composed of 22 antigens: three pairs
f antithetical antigens, Dia and Dib, Wra and Wrb, Wu  and
ISK, and 16 very low frequency antigens.1 Wra and Wrb anti-
ens are related to a SNP in exon 16 (1972G>A) that encodes a
ysine in Wra or a glutamic acid in Wrb at amino acid position
58.2
The Wra antigen, ﬁrst described by Holman in 1953, has an
ncidence of around 1 in 1000 in Caucasian populations, but it
s not reported in other ethnic groups.3 Although the Wra anti-
en has a very low incidence, anti-Wra is a relatively common
ntibody since it is often a naturally occurring antibody.4 The
escribed incidence of anti-Wra in the sera of normal donors
aries in different studies; it has been estimated at 1 of 100
n healthy volunteer blood donors.5 The immunoglobulin (Ig)
lass of anti-Wra can be IgM, IgG or IgM plus IgG. Alloanti-Wra
s rarely involved in hemolytic transfusion reactions, however
here are some cases reporting hemolytic disease of the fetus
nd newborn (HDFN) caused by anti-Wra.1
Antibodies against low-incidence antigens, including anti-
ra, are difﬁcult to identify, because the screening and panel
ells rarely express these antigens.6,7 Hence, little is known
bout the frequency of anti-Wra in many  populations. The
nowledge of the molecular basis of the Diego blood group
ystem and the development of molecular assays to identify
he DI alleles has allowed the frequency of these alleles to be
ssessed in different populations. The aim of this study was
o determine the frequency of the Wra antigen and anti-Wra
n a Brazilian population of blood donors.ethods
 total of 1662 blood samples were obtained from healthy vol-
nteer Brazilian blood donors at the Associac¸ão Beneﬁcente
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Figure 1 – GeneMapper electropherogram of representative S 1 5;3  7(5):316–319 317
de Coleta de Sangue (Colsan), São Paulo, Brazil. The popula-
tion studied was from Southeast of Brazil and it is composed
of a highly admixed population.
Molecular  analysis
DNA was extracted using the QIAmp DNA Mini Kit (Qiagen®
Inc. Valencia, CA, USA) according to the manufacturer’s
instructions. To determine the WR*A and WR*B alleles and
predict the frequency of the Wra antigen, genotyping was per-
formed using a previous described SNaPshot® protocol (Latini
et al.8). Fragment analyses were performed in a 3500xL Genetic
Analyzer (Applied Biosystem, Foster City, CA, USA) as shown
in Figure 1.
Antibody  screening
In order to investigate the occurrence of anti-Wra, serum sam-
ples from 1049 blood donors (638 male and 411 female donors)
were initially cross-matched with a Wr(a+) red blood cell (RBC)
from our collection in a gel test by an automated system
(WADiana® 8XT, Grifols, Barcelona, Spain). The presence of
anti-Wra in positive cross-matches was conﬁrmed with two
sources of Wr(a+) RBCs from commercial panels (BioRad®,
Lagoa Santa, Brazil).
Immunoglobulin  classes
To determine the Ig classes (IgG or IgM), the serum was
treated with dithiothreitol (DTT, Sigma-Aldrich, Brazil). The
IgG isotype classiﬁcation was performed in a gel test using
the IgG1/IgG3 card (BioRad®, Lagoa Santa, Brazil).
Monocyte  monolayer  assay
aTo predict the clinical signiﬁcance of anti-Wr , the mono-
cyte monolayer assay (MMA) was performed as previously
described9 in two samples with anti-Wra classiﬁed as IgG1 and
one sample classiﬁed as IgG3. Using an optical microscopy, 600
DO*2
DO*5
DO*4
Vel+
NaPshot fragment in the analysis of the Wr(a+) donor.
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ativFigure 2 – Monocyte monolayer assay slides (1000×). (A) Neg
monocytes were counted to determine the percentage of reac-
tive monocytes (RBC adhered and phagocytized). MMA results
<4% were considered negative while results ≥4% were consid-
ered positive.
Results
Wra antigen
Of the 1662 genotyped blood samples, only one sample pre-
sented the WR*A allele in heterozygous. It was genotyped as
WR*A/WR*B predicting the Wr(a+b+) phenotype.
Anti-Wra
Anti-Wra was detected in 34 samples from 1049 screened
blood donors representing a frequency of 3.24%. Regarding the
Ig classes, 8/34 (23.5%) were IgG and 26/34 (76.5%) were IgM. Of
the eight IgG anti-Wra, four were classiﬁed as IgG1 and one
was isotyped as IgG3. Three samples were not classiﬁed as
IgG1 or IgG3; these are probably IgG2 or IgG4, Ig classes that
are not involved in severe transfusion reactions. As shown in
Table 1, a higher frequency of anti-Wra was observed in female
donors (p = 0.0036, Fisher’s exact test).
Table 1 – Frequency of anti-Wra and immunoglobulin (Ig)
class.
Ig class Isotype Donor Total
Female Male
IgG IgG1  3 1 4
IgG3 0 1 1
IgG2 or IgG4 3 0 3
IgM – 16 10 26
Total 22 12 34e control and (B) Monocyte monolayer assay with anti-Wra.
MMA results (Figure 2) show that Wra antibodies classiﬁed
as IgG can potentially be clinically signiﬁcant, as IgG1 antibod-
ies presented 7–7.5% of reactive monocytes and 12.7% of IgG3
had reactive monocytes.
Discussion
This study shows novel information regarding the presence of
anti-Wra in a Brazilian population of blood donors. Although
the frequency of the Wra antigen (1:1662) is lower than that
previously reported in Europeans (1:1000),3 the occurrence of
anti-Wra was higher (1:31) when compared to other studies
where it ranged from 1 in 80 to 1 in 200. The frequency of anti-
Wra found in this study is similar to that found in Spain (1:37),
however the presence of the antigen in Spanish population is
around 2-times (1:785)6 the frequency found in Brazilians.
The mechanisms involved in anti-Wra production are still
unclear. Some authors believe that, besides the alloimmu-
nization in response to antigen exposure, certain proteins
that can cross-react with the Wra antigen are formed
when the immune system becomes more  active.7 Situations
described to be involved in anti-Wra alloimmunization are
also related to immune system activation, including preg-
nancy, autoimmune hemolytic anemia and patients with
other RBC antibodies.7 Therefore, our hypothesis is that the
difference in anti-Wra distribution between genders could be
associated to pregnancy, as anti-Wra was found in 5.2% of
women and 1.8% of men.
The nature of alloimmunization might determine the anti-
body behavior. Our results comprising Ig class showed that
IgM anti-Wra was the predominant class, corroborating with
the hypothesis of it being a naturally occurring antibody. On
the other hand, four IgG1 and one IgG3 anti-Wra with possi-
able clinical signiﬁcance were identiﬁed. Even though anti-Wr
is described to rarely cause HDFN or hemolytic transfusion
reactions, probably due to the fact that anti-Wra are usually
nonimmune antibodies10 1.4% of anti-Wra found in this study
er. 2 0
c
t
r
i
o
d
B
t
q
t
m
C
T
r
1rev bras hematol hemot
an be of clinical signiﬁcance. Due to the low incidence of
he Wra antigen and the low risk of hemolytic transfusion
eaction, the use of screening panels containing Wr(a+) RBCs
s not required. Thereby Wra incompatible transfusion can
ccur, but few cases of hemolytic transfusion reaction were
escribed, been estimated to be 1 in 500,000.11
In summary, the Wra antigen has a very low frequency in
razilian blood donors and anti-Wra has a higher frequency
han reported in other populations. Considering the low fre-
uency of the antigen and the few cases of mild HDFN related
o anti-Wra, clinical impact is discussable as well the require-
ent of RBC reagent to identify them.
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